Infectious Disease | COVID-19
13 March 2020
All local recommended safety guidelines followed at the time of interview.
In the wake of the coronavirus outbreak, quick action is needed to develop solutions for testing a pathogen never seen before and to ultimately provide healthcare workers with options for diagnosis. Since January, QIAGEN has been providing instruments and consumables to support the detection of the virus.
At the beginning of an outbreak with a novel pathogen, detection is difficult because the new virus does not have an already identified genetic sequence. The main challenge is that a new virus has never been on the radar, leading to a need for commercial tests to be developed from scratch– and quickly. “Multiple components must be sourced from various vendors for labs to develop and validate tests,” explains Alex Vial, applications specialist at QIAGEN. It’s not a one-size-fits-all solution either: different types of tests are necessary depending on the specific situation. These cases can occur at airports, emergency rooms, and large hospital labs, for example, turning these seemingly normal settings into a hot spot for testing, and health care personnel continue to test for respiratory illnesses in a variety of ways.
QIAstat-Dx Respiratory 2019-nCoV Panel
Real-time PCR testing
Quality sample extraction for quality results
QIAGEN’s Global response to coronavirus
We recognize that there are concerns about allocations for certain products used in testing. As soon as this outbreak emerged, QIAGEN began responding to calls from customers in need of testing solutions. The emergence and rapid spread of COVID-19 has created extraordinary demand, straining QIAGEN’s capacity, as well as that of other companies and healthcare organizations
On March 12, customers were informed about the measures taken by QIAGEN. “We have scaled up production to respond to the rapid spread of COVID-19, moving to 24-hour, seven-day-a-week operations at two key sites, investing to expand capacity by 70% and adding staff. Our top priority is producing the QIAamp and EZ1 sample technologies recommended in the U.S. Centers for Disease Control guidelines for testing, as well as the new QIAstat-Dx cartridges. We are working closely with laboratories, hospitals and other customers around the world to assess their flexibility, timing, and quantity needs,” says Thierry Bernard, Chief Executive Officer of QIAGEN.
A rapid response to coronavirusQIAGEN is responding as quickly as possible to provide solutions to contain the spread of the coronavirus.
Analyzing the ancient origins of rare genetic diseasesEsteemed geneticist, Dr. Bisgin, uses QIAGEN bioinformatic tools to help find a cure for rare genetic diseases in Turkey.